Chromocell Therapeutics Corporation

Equities

CHRO

US1711261057

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 01:40:00 18/05/2024 am IST			5-day change	1st Jan Change
1.75 ^USD	-12.94%		-4.37%	0.00%

15/05	Chromocell Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/04	Chromocell Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.

February 15, 2024 at 10:30 am IST

Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.

Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 1,100,000
PriceRange: $6
Discount Per Security: $0.42

Transaction Features: Sponsor Backed Offering

Latest news about Chromocell Therapeutics Corporation

Chromocell Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	16/05	CI
Chromocell Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	17/04	CI
Chromocell Therapeutics Corporation Announces Formal Launch of Eye Pain Treatment Program	21/03	CI
Chromocell Therapeutics Corp. Appoints Frank Knuettel, Interim CEO, as Permanent CEO	18/03	CI
Transcript : Chromocell Therapeutics Corporation Presents at Sidoti Small-Cap Virtual Conference, Mar-13-2024 02:30 PM	14/03
Chromocell Therapeutics Corporation has completed an IPO in the amount of $6.6 million.	15/02	CI
Chromocell Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/01	CI
Chromocell Therapeutics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	02/23/02	CI
Chromocell Therapeutics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	30/23/30	CI
Chromocell Therapeutics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02	CI

Chart Chromocell Therapeutics Corporation

Duration

Period

Chart Chromocell Therapeutics Corporation

More charts

Company Profile

Chromocell Therapeutics Corporation is a clinical-stage biotech company, which is focused on developing and commercializing therapeutics to alleviate pain. The Company's clinical focus is to selectively target the sodium ion-channel, NaV1.7, as well as other receptors in the NaV family. Its lead compound, CC8464, is designed to address both the underlying condition and mitigate the burning pain symptoms, which erythromelalgia (EM) patients experience by blocking the NaV1.7 sodium channel. CC8464 has completed Phase I study. A total of approximately 207 healthy subjects have been dosed in four Phase I studies (CC8464-1001, CC8464-1002, CC8464-1003, and 1807-CL-0102) with study treatment.

Sector

Biotechnology & Medical Research

Calendar

21/05/2024 - Alliance Global Partners Healthcare Showcase

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CHROMOCELL THERAPEUTICS CORPORATION	0.00%	11.81M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs